{"id":840191,"date":"2025-04-22T16:15:37","date_gmt":"2025-04-22T20:15:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/"},"modified":"2025-04-22T16:15:37","modified_gmt":"2025-04-22T20:15:37","slug":"nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/","title":{"rendered":"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025<\/b><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET.\n<\/p>\n<p>\nThe U.S. Food and Drug Administration assigned taletrectinib\u2019s New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025.\n<\/p>\n<p>\nInvestors and the general public are invited to listen to a live webcast of the call at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.nuvationbio.com%2Finvestors%2F&amp;esheet=54241079&amp;newsitemid=20250422970092&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestors.nuvationbio.com%2Finvestors%2F&amp;index=1&amp;md5=3b0c755bc807039533710432513c519a\">https:\/\/investors.nuvationbio.com\/investors\/<\/a>. Materials related to the call will be available prior to the start of the conference call. A replay of the webcast will be available after the conference call concludes.\n<\/p>\n<p><b>About Nuvation Bio<\/b><\/p>\n<p>\nNuvation Bio is a global oncology company focused on solving some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients\u2019 lives. Our diverse pipeline includes taletrectinib, a third-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor.\n<\/p>\n<p>\nNuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world\u2019s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nuvationbio.com&amp;esheet=54241079&amp;newsitemid=20250422970092&amp;lan=en-US&amp;anchor=www.nuvationbio.com&amp;index=2&amp;md5=23cc8ef64cd001d25bb93c7de2d4eea3\">www.nuvationbio.com<\/a> or follow the company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnuvationbio%2F&amp;esheet=54241079&amp;newsitemid=20250422970092&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=5e7f11b66f9ed2865b8a522ae1baefde\">LinkedIn<\/a> and X (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2Fnuvationbioinc&amp;esheet=54241079&amp;newsitemid=20250422970092&amp;lan=en-US&amp;anchor=%40nuvationbioinc&amp;index=4&amp;md5=c566477da88b6714190033042bb0ac89\">@nuvationbioinc<\/a>).\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250422970092\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250422970092\/en\/<\/a><\/span><\/p>\n<p><b>Nuvation Bio Investor Contact:<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:ir@nuvationbio.com\">ir@nuvationbio.com<\/a><\/p>\n<p><b>Nuvation Bio Media Contact:<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:media@nuvationbio.com\">media@nuvationbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250422970092\/en\/1371310\/3\/NUVB_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 NEW YORK&#8211;(BUSINESS WIRE)&#8211; Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib\u2019s New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https:\/\/investors.nuvationbio.com\/investors\/. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-840191","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 NEW YORK&#8211;(BUSINESS WIRE)&#8211; Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib\u2019s New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https:\/\/investors.nuvationbio.com\/investors\/. &hellip; Continue reading &quot;Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T20:15:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025\",\"datePublished\":\"2025-04-22T20:15:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/\"},\"wordCount\":329,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/\",\"name\":\"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-04-22T20:15:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/","og_locale":"en_US","og_type":"article","og_title":"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 - Market Newsdesk","og_description":"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 NEW YORK&#8211;(BUSINESS WIRE)&#8211; Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib\u2019s New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https:\/\/investors.nuvationbio.com\/investors\/. &hellip; Continue reading \"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-22T20:15:37+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025","datePublished":"2025-04-22T20:15:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/"},"wordCount":329,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/","name":"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-04-22T20:15:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250422970092r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvation-bio-to-report-results-for-first-quarter-2025-and-provide-business-update-on-may-7-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/840191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=840191"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/840191\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=840191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=840191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=840191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}